Ultragenyx to Present Setrusumab (UX143) Update at ASBMR 2023 Including New Data from Phase 2/3 Orbit Study in Osteogenesis Imperfecta (OI)
09 oct. 2023 08h00 HE
|
Ultragenyx Pharmaceutical Inc.
Ultragenyx to share data from late-stage program evaluating setrusumab (UX143) in osteogenesis imperfecta at American Society for Bone and Mineral Research
Ultragenyx to Present Pipeline Update at Analyst Day on Monday, October 16, 2023
05 oct. 2023 08h00 HE
|
Ultragenyx Pharmaceutical Inc.
Ultragenyx will host Analyst Day webcast on Monday, October 16, 2023 to provide updates on programs for osteogenesis imperfecta, Angelman syndrome and more
Ultragenyx lance EVKEEZA (évinacumab pour injection) au Canada pour traiter l’hypercholestérolémie familiale homozygote (HFHo)
25 sept. 2023 17h13 HE
|
Ultragenyx Pharmaceutical Inc.
TORONTO, 25 sept. 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ : RARE), compagnie biopharmaceutique spécialisée dans le développement et la commercialisation de nouveaux...
Ultragenyx Launches Evkeeza® (evinacumab for injection) in Canada for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)
25 sept. 2023 17h13 HE
|
Ultragenyx Pharmaceutical Inc.
TORONTO, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
20 sept. 2023 17h00 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Zur Behandlung der homozygoten familiären Hypercholesterinämie (HoFH): Ultragenyx führt Evkeeza® (Evinacumab) in Deutschland ein
01 sept. 2023 02h00 HE
|
Ultragenyx Pharmaceutical Inc.
BERLIN, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung neuer Therapien für seltene genetische...
Ultragenyx to Participate at Investor Conferences in September
31 août 2023 09h00 HE
|
Ultragenyx Pharmaceutical Inc.
Citi BioPharma Conference on September 6 in Boston Morgan Stanley Healthcare Conference on September 12 in New York City NOVATO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
18 août 2023 17h00 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Aug. 18, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Reports Second Quarter 2023 Financial Results and Corporate Update
03 août 2023 16h00 HE
|
Ultragenyx Pharmaceutical Inc.
Second quarter 2023 total revenue of $108.3 million, Crysvita® revenue of $83.0 million and Dojolvi® revenue of $16.5 million Total revenue grew 21% and total Crysvita revenue grew 20% versus the...
Ultragenyx Announces Initiation of Dosing in Second Cohort of Pivotal Phase 1/2/3 Cyprus2+ Trial Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
31 juil. 2023 08h00 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., July 31, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced it has begun dosing the second dose-escalation cohort in its pivotal Phase 1/2/3...